Quantcast
Last updated on April 24, 2014 at 11:09 EDT

TPI to Host Third Quarter Fiscal Year 2013 Earnings Conference Call on Wednesday, May 15, 2013 at 9 a.m. ET

May 6, 2013

CHENGDU, China, May 5, 2013 /PRNewswire/ — Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the third quarter of fiscal year 2013 ending March 31, 2013 to be held at 9:00 a.m. ET on Wednesday, May 15(th), 2013.

Interested parties may access the call by dialing

    Toll free:                         1-877-941-1427

    International:                     1-480-629-9664

The conference ID is 4617492. It is advisable to dial in approximately 5 minutes prior to the start of the call.

A replay will be available by calling

    Toll free:                        1-877-870-5176

    International:                    1-858-384-5517

    From:                             05/15/13 @ 12:00 pm E.T.

    To:                               05/29/13 @ 11:59 pm E.T.

    Replay Pin Number:                                 4617492

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid’s website at the following link: http://public.viavid.com/index.php?id=104577

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list (EDL) of China. TPI’s pipeline targets various high incidence healthcare indications. For more information about TPI, please visit: http://www.tianyinpharma.com

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email: ir@tpi.asia

Tel: +86-28-8551-6696 (Chengdu, China)
+86-134-3655-0011 (China)

Address:

Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China

SOURCE Tianyin Pharmaceutical Co., Inc.


Source: PR Newswire